Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report sent to investors on Monday morning. The firm issued a sell rating on the stock.

Separately, Alliance Global Partners increased their price target on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 22nd.

Tonix Pharmaceuticals Stock Down 5.9 %

Shares of TNXP opened at $0.15 on Monday. The company has a quick ratio of 0.72, a current ratio of 1.15 and a debt-to-equity ratio of 0.13. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $22.14. The company has a market cap of $19.94 million, a PE ratio of 0.00 and a beta of 2.08. The business has a fifty day moving average of $0.18 and a 200 day moving average of $1.83.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Friday, August 16th. The company reported ($19.28) EPS for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The firm had revenue of $2.21 million for the quarter, compared to analysts’ expectations of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. On average, sell-side analysts expect that Tonix Pharmaceuticals will post -18 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC grew its holdings in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.